Sunshine Biopharma files draft information statement on potential reverse stock split up to 1-for-20

• Sunshine Biopharma shareholders authorized an amendment to permit a reverse stock split of common shares at a ratio up to 1-for-20.
• The board would set the final ratio at a whole number up to 1-for-20, or abandon the split.
• As of Sept. 15, 2026, 4,310,301 common shares were outstanding; the split would cut that to 215,515–2,155,150.
• Fractional shares would be rounded up to the next whole share.
• Outstanding warrants would be adjusted for the split ratio, with per-share exercise prices and share counts recalculated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-007195), on September 16, 2026, and is solely responsible for the information contained therein.